

## Your Vaccine Specialists. We are the Experts in Cold Chain Vaccine Delivery with Full In-Coolroom Processing

We include **Heat** and **most importantly Freeze** Temperature Monitors in every vaccine order we ship.

**Without a Freeze Monitor** how can you be sure your vaccines are arriving **without compromise?**



**When it comes to vaccines correct storage and transport is paramount. Because, even one broken link in the chain can mean your vaccines aren't viable.**

At Team Medical, we adhere to the 'Strive for 5' National Vaccine Storage Guidelines. Below is a snapshot of what we do to ensure your vaccines are kept at the correct temperature from the moment we receive the stock to when the stock is delivered.



**We are your vaccine specialists. Only Team Medical with our family of BP, Capital and Alpha Medical take all of these steps to ensure the viability of your vaccines.**

# ADACEL PRE-FILLED SYRINGE: AVAILABLE IN 10 PACK OR SINGLE PACK<sup>1</sup>

**Adacel®**  
Pertussis Vaccine Acellular Combined with  
Diphtheria and Tetanus Toxoids (adsorbed)

## There are two presentations of Adacel available for purchase:<sup>1</sup>

- Adacel PFS 0.5 mL x 10
- Adacel PFS 0.5 mL x 1



Adacel PFS 0.5 mL x 10

Adacel PFS 0.5 mL x 1

## Space saving for healthcare practitioners

Save fridge space with the Adacel 10 pack,  
which is more compact than 10 single syringe packs



## Simplicity for healthcare practitioners

Adacel pre-filled syringe uses the luer lock safety system.  
A luer lock syringe:

- Provides a more secure connection than a luer slip syringe
- Prevents vaccine leakage<sup>2</sup>
- Prevents accidental removal of the needle



**PBS Information:** This product is not listed on the PBS. This product is listed on the National Immunisation Program (NIP).  
Refer to the NIP Schedule and your State or Territory Health Department for details.



ADACEL is on the NIP for maternal immunisation during pregnancy.

For healthcare professionals only.

PLEASE REVIEW FULL ADACEL PRODUCT INFORMATION BEFORE PRESCRIBING.

Scan QR code for full ADACEL product information.

For medical enquiries contact Sanofi Medical Information 1800 818 806. Full Product Information is available from Sanofi or [www.medsinfo.com.au/product-information/document/Adacel\\_PI](http://www.medsinfo.com.au/product-information/document/Adacel_PI)

**Reference:** 1. Adacel® Australian approved Product Information. 2. NHS Clinical Evaluation Team. Clinical review: Syringes – hypodermic Luer slip. Available at: <https://www.media.supplychain.nhs.uk/media/Clinical-Review-for-3-Piece-Luer-Slip-Syringes-V2-May-2018.pdf>. Accessed January 2024.

Sanofi-aventis australia Pty Ltd. ABN 31 008 558 807. Trading as Sanofi. Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113. Customer Service Enquiries 1800 829 468.

MAT-AU-2400136-1.0. Ward7 SAAD32032M. Date of approval: February 2024.

**sanofi**




SANAV350693	Each	5+	10+	20+
		\$41.50	\$39.50	\$38.75
				\$35.25
SANAV350694	Box/10	2+	10+	20+
		\$387.50	\$365	\$365




SANAV8190	Each	5+	10+	20+
		\$70.75	\$69.25	\$67.25
				\$63.95



SANAV8050	Each	5+	10+	20+
		\$65.95	\$63.95	\$61.95
				\$54.95




SANAV8140	Each	5+	10+	20+
		\$50.25	\$49.50	\$49.50
				\$49.50



SAN350691	Each	5+	10+	20+
		\$69.95	\$68.45	\$64.50
				\$61.25



SANAV8040	Each	5+	10+	20+
		\$118.50	\$117.50	\$115.85
				\$111.90



SANAV8020	Each	5+	10+	20+
		\$73.50	\$71.25	\$69.50
				\$64.95




SANAV352379	Each	3+	10+	20+
		\$114.95	\$109.95	\$109.95
				\$109.95




## sanofi INFLUENZA VACCINES



SANAV7740  
Box/5



SANAV345512  
Box/5







# Travel smart, travel safe. Don't let missed vaccinations ruin their holiday.<sup>1-4</sup>



**PBS Information:** Avaxim and Typhim Vi and Verorab are not listed on the National Immunisation Program (NIP) or the PBS.

**PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.**  
Please scan the QR codes to read the full prescribing information.

**TYPHIM Vi®**  
Polysaccharide Typhoid Vaccine



**AVAXIM®**  
Inactivated Hepatitis A Vaccine



**VERORAB®**  
Inactivated Rabies Vaccine



**Abbreviations:** NIP: National Immunisation Program; PBS: Pharmaceutical Benefits Scheme; PI: product information.

**References:** 1. [Smartraveller.gov.au](https://www.smartraveller.gov.au/before-you-go/health/vaccinations) (Australian Government Department of Foreign Affairs and Trade). Vaccinations and preventative health. 2022. <https://www.smartraveller.gov.au/before-you-go/health/vaccinations>. Accessed January 2024. 2. Australian Immunisation Handbook (AIH). Hepatitis A. 2023. <https://immunisationhandbook.health.gov.au/contents/vaccine-preventablediseases/hepatitis-a>. Accessed January 2024. 3. Australian Immunisation Handbook (AIH). Typhoid fever. 2023. <https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/typhoidfever>. Accessed January 2024. 4. Australian Immunisation Handbook (AIH). Rabies and other lyssaviruses. 2024. <https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/rabies-and-other-lyssaviruses>. Accessed January 2024.

sanofi-aventis australia pty ltd. ABN 31 008 558 807. Trading as SANOFI. 12-24 Talavera Rd, Macquarie Park NSW 2113. Customer Service 1800 829 468. MAT-AU-2400210-VI.O. SANA8682. Date of preparation: February 2024.

**sanofi**





## WHEN THEY'RE PREPARING TO TRAVEL, MENQUADFI® IS READY TO PROTECT THEM

THE **LATEST INNOVATION** FROM SANOFI IN MenACWY VACCINES<sup>1,2</sup>

MENQUADFI® vaccine prevents invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W and Y.<sup>1</sup> MENQUADFI® offers:



A high immune response  
across all four serogroups  
A, C, W and Y<sup>1,3-7</sup>



Ready-to-use  
formulation – no  
reconstitution required<sup>1,8</sup>



Indicated for use  
from  
12 months of age<sup>1</sup>

\*Seroprotection, defined as hSBA titres  $\geq 1:8$ , was evaluated at 30 days after injection.<sup>1,3-7</sup>

Protect your patients before they travel.

**DISCOVER MORE ABOUT MENQUADFI® AT [VAXIPLACE.COM.AU](https://vaxiplace.com.au)**

**PBS information: This product is not listed on the PBS or NIP**

Please review full Product Information before prescribing. Scan QR code for full Product Information.



hSBA, serum bacterial assay using human complement; MenACWY, quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate.

**References:** **1.** MenQuadfi® Australian Product Information. **2.** Kensinger RD & Hauser SL. MenQuadfi patent application. 2016. Available at: [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018045286&\\_cid=P20-LBU0CP-32803-1](https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018045286&_cid=P20-LBU0CP-32803-1). Accessed December 2022. **3.** Baccarini CI et al. *Pediatr Infect Dis J* 2020; 39: 955-960. **4.** Chang L-J et al. *Vaccine* 2020; 38:3560-69. **5.** Anez G et al. *Hum Vaccin Immunother* 2020; 16: 1292-98. **6.** Dhingra MS et al. *Vaccine* 2020; 38: 5194-5201. **7.** Kirstein J et al. *Hum Vaccin Immunother* 2020; 16: 1299-1305. **8.** Martinon-Torres F et al. *Expert Rev Vaccines* 2021; 20: 1123-1146. ©2023 sanofi-aventis australia Pty Ltd trading as Sanofi. ABN 31 008 558 807. Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. [www.sanofi.com.au](http://www.sanofi.com.au) MAT-AU-2203511. McCann Health SAMQ27301M. Date of preparation: January 2023.

# ACCESS TO HPV VACCINATION DOESN'T END AT SCHOOL

Up to one in five adolescents and young adults may have missed HPV vaccination at school.<sup>1</sup>

Are your patients up to date?

**GARDASIL® 9**  
is indicated  
for people aged  
9–45 years<sup>2</sup>

- ▶ GARDASIL® 9 comprises the nine HPV genotypes [6, 11, 16, 18, 31, 33, 45, 52, 58] associated with more than 90% of cervical cancers, 80% of anal cancers and 90% of genital warts.<sup>2-5</sup>
- ▶ GARDASIL® 9 is funded on the National Immunisation Program for people aged 12 to ≤25 years of age.<sup>6</sup>
- ▶ HPV vaccination is recommended beyond adolescence and young adulthood for previously unvaccinated men who have sex with men<sup>^</sup> and people with severely immunocompromising conditions (3 doses)<sup>5\*</sup>

<sup>^</sup>Adults 26 years and over are recommended to receive a three-dose course

<sup>\*</sup>GARDASIL® 9 registered age indication 9–45 years<sup>3</sup>

  
**GARDASIL® 9**  
[Human Papillomavirus  
9-valent Vaccine, Recombinant]

**PBS Information:** This Product is listed on the National Immunisation Program (NIP) for people aged 12–25 years. Refer to NIP Schedule.

Before prescribing, please review the Product Information available at [cslseqirus.com.au/products](https://cslseqirus.com.au/products)

**MINIMUM PRODUCT INFORMATION:** GARDASIL® 9 [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant] **Indications:** GARDASIL 9 is indicated in females aged 9 to 45 years<sup>3</sup> for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58. GARDASIL 9 is indicated in males aged 9 to 45 years<sup>3</sup> for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. **Evidence of vaccine efficacy** is based on the core efficacy population of females aged 16 to 26 years. Immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years) and to females over 26 years of age. **Contraindications:** Hypersensitivity to active or inactive substances of GARDASIL 9 or GARDASIL. Individuals who develop symptoms indicative of hypersensitivity after a dose of GARDASIL 9 or GARDASIL should not receive further doses. **Precautions:** Febrile illness, impaired immune responsiveness, thrombocytopenia or any coagulation disorder. This vaccine is not intended to be used for active treatment and will not protect against diseases that are not caused by HPV or non-vaccine genotypes. Routine cervical screening and detection and removal of cervical lesions should be continued in individuals who receive the vaccine. Syncope, sometimes associated with falling, has occurred after HPV vaccination. Vaccinees should be carefully observed for approximately 15 minutes after administration. Immunologic response may be diminished in immunocompromised individuals. **Use in Pregnancy (Category B2):** Not recommended for use in pregnant women. Pregnancy should be avoided during the vaccination regimen. **Use in Lactation:** May be administered to lactating women. It is not known whether vaccine antigens or antibodies induced by the vaccine are excreted in human milk. **Interactions with other medicines:** See Product Information. Use of hormonal contraceptives did not appear to affect the immune responses to GARDASIL 9. Immunosuppressive therapies may reduce the immune responses to vaccines. **Adverse Effects:** Injection site (pain, swelling, erythema, bruising, pruritus, mass, haemorrhage, induration, hematoma, warmth, reaction), headache, fever, nausea, dizziness, fatigue, diarrhoea, myalgia, influenza, upper respiratory tract infection, oropharyngeal and upper abdominal pain. **Post-marketing experience:** The following adverse reactions have been spontaneously reported during post-approval use: GARDASIL 9 - syncope sometimes accompanied by tonic-clonic movements, vomiting; GARDASIL - cellulitis, idiopathic thrombocytopenic purpura, lymphadenopathy, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria, acute disseminated encephalomyelitis, dizziness, Guillain-Barré syndrome, headache, nausea, arthralgia, myalgia, asthenia, chills, fatigue, malaise. **Dosage and Administration:** Administered intramuscularly at day 0 and then at 2 and 6 months after initial dose. In clinical studies, efficacy has been demonstrated in individuals who have received all 3 doses within a 1-year period. Alternatively, in individuals 9 through 14 years of age, GARDASIL 9 can be administered according to a 2-dose schedule; the second dose should be administered between 5 and 13 months after the first dose. If the second vaccine dose is administered earlier than 5 months after the first dose, a third dose should always be administered. Based on Approved Product Information dated 11 April 2023. AU-GAR9-23-0011

**REFERENCES:** 1. NCIRS. Impact evaluation of Australian national HPV vaccination program 2021. 2. Gardasil 9 Approved Product Information. 3. Patel C *et al.* *Euro Surveill* 2018; 23(41). 4. Hillman RJ *et al.* *Int J Cancer*. 2014;135(4):996–1001. 5. ATAGI Australian Immunisation Handbook 2022 available at: [immunisationhandbook.health.gov.au](https://immunisationhandbook.health.gov.au) accessed June 2023. 6. NIP Schedule 6 Feb 2023 Available at: [health.gov.au/resources/publications/national-immunisation-program-schedule](https://health.gov.au/resources/publications/national-immunisation-program-schedule) Accessed June 2023. Seqirus (Australia) Pty Ltd, Melbourne, Victoria. www.cslseqirus.com.au. ABN: 66 120 398 067; distributor for Merck, Sharp and Dohme (Australia) Pty Ltd. Medical Information: 1800 642 865. GARDASIL® 9 is a registered trademark of Merck Sharp & Dohme Corp LLC., Rahway, NJ, USA. Seqirus® is a trademark of Seqirus UK Limited or its affiliates. Copyright © (2023) Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. Date of preparation: November 2023. AU-GAR9-23-0016. 001994.

**CSL Seqirus**



## DUKORAL®

Oral, Inactivated Cholera vaccine

SANAV8170	Each	5+	10+	20+
	\$66.80	\$65.75	\$63.70	\$62.40
SANAV8172	Pack/2	5+	10+	20+
	\$136.60	\$131.50	\$127.40	\$124.80



## GARDASIL™ 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)

CSL80890101	Each	5+	10+
	\$234.00	\$223.60	\$217.00



## H-B-VAX II

Hepatitis B vaccine  
(recombinant)

Paediatric CSL80860501	Each	5+	10+	20+
	\$28.25	\$26.28	\$25.85	\$24.90
Adult CSL80860401	Each	5+	10+	20+
	\$15.50	\$14.85	\$14.30	\$13.80



## JESPECT®

CSL08550101	Each	3+	5+	10+
	\$102.95	\$99.84	\$94.65	\$94.65



## MSD M-M-R II (Measles, Mumps, & Rubella Virus Vaccine Live)

CSL80740001	Each	5+	10+	20+
	\$38.10	\$35.80	\$34.25	\$33.00



## PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent)

CSL7860101	Each	5+	10+
	\$63.50	\$62.35	\$57.15




## Q-vax® Q FEVER VACCINE

Skin Test CSL9960501	Each	3+	Vaccine CSL9800101	Each	5+
	\$36.10	\$34.25		\$138.25	\$130.95



## Rabipur® Rabies Vaccine

CSL8510101	Each	5+	10+
	\$134.50	\$128.95	\$124.00



## VAQTA® Hepatitis A vaccine, inactivated Adult Paediatric

Paediatric CSL80610002	Each	5+	10+	20+
	\$47.75	\$43.50	\$44.25	\$41.50
Adult CSL80600001	Each	5+	10+	20+
	\$69.60	\$67.50	\$65.50	\$62.40



## VARIVAX® VARICELLA VIRUS VACCINE LIVE (Oka/Merck)

CSL80740201	Each	5+	10+	20+
	\$62.85	\$61.30	\$60.25	\$58.20



## CSL Seqirus INFLUENZA VACCINES

### Afluria® Quad Inactivated quadrivalent influenza vaccine

CSL49062227  
Box/10



### FLUCELVAX® QUAD Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell culture)

CELL  
BASED

CSL10050830  
Box/10





**AREXVY**  
(RESPIRATORY SYNCYTIAL VIRUS  
VACCINE RECOMBINANT, ADJUVANTED)

GSK707274	Each	5+	10+	
		\$339.00	\$299.00	\$299.00



**BEXSERO**  
Meningococcal Group B Vaccine  
(recombinant, component, adsorbed)

NOVBEX001	Each	5+	10+	
		\$141.00	\$136.00	\$129.00



**boostrix**  
Combined diphtheria-tetanus-acellular  
pertussis (dTpa) vaccine

GSK61613	Each	5+	10+	20+
		\$41.85	\$39.80	\$38.75 \$36.50



**boostrix<sup>ipv</sup>**  
combined diphtheria, tetanus, acellular pertussis and poliovirus vaccine

GSK61617	Each	5+	10+	20+
		\$74.35	\$72.75	\$72.00 \$69.60



**engerix<sup>b</sup>**  
hepatitis B surface antigen recombinant (yeast)

Adult GSK61682	Each	5+	10+	20+
		\$28.25	\$26.75	\$25.85 \$24.90
Adult GSK61683	Box/10	3+		
		\$259.00	\$249.50	
Junior GSK61782	Each	5+	10+	20+
		\$15.50	\$14.85	\$14.30 \$13.75



**havrix<sup>®</sup>**  
inactivated hepatitis A virus vaccine

Adult GSK61688	Each	5+	10+	20+
		\$69.60	\$67.50	\$65.50 \$62.40
Junior GSK61687	Box/10	5+	10+	20+
		\$47.75	\$45.50	\$44.25 \$41.50



**MALARONE**  
atovaquone/ proguanil hydrochloride

Adult GSK61427	Box/12	2+		Junior GSK61428	Box/12	2+
		\$79.71	\$77.58			\$25.47 \$23.76

**MENVEO**  
Meningococcal (Groups A, C, W-135 and Y)  
Oligosaccharide CRM197 Conjugate Vaccine

CSL8520004	Each	5+	10+	20+
		\$83.85	\$82.45	\$75.85 \$72.75



**Priorix**  
Measles, mumps, rubella vaccine, live

GSK61660	Each	5+	10+	20+
		\$29.10	\$28.00	\$26.45 \$25.45





GSK706262	Each	5+	
	\$311.00	\$301.00	



<b>Adult</b> GSK61657	Each	5+	10+	20+
	\$83.60	\$82.65	\$80.50	\$77.95
<b>Junior</b> GSK61656	Each	5+	10+	20+
	\$55.06	\$51.95	\$49.85	\$46.75



GSK61664	Each	5+	10+	20+
	\$62.85	\$61.30	\$60.25	\$58.20




## Travel continues to grow!

Make sure your patients are ready for their next trip, whether it involves sipping on a cocktail in Bali, visiting the vibrant markets of India or taking in the tranquility of Fiji. We have your travel vaccine needs covered.




SANAV329405	Each	5+	10+
	\$307.00	\$296.00	\$275.00



BIOC08293438	Box/8	2+	10+	20+
	\$105.28	\$94.65	\$94.65	\$94.65
BIOC16293438	Box/16	2+	10+	20+
	\$158.46	\$154.20	\$154.20	\$154.20



BIOBC01389746	Each	5+	10+	20+
	\$147.50	\$145.20	\$140.60	\$137.60



CSL04180803	Each	5+	
	\$59.00	\$57.20	



## Nimenrix™

Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine

Each	5+	10+	20+
\$69.65	\$68.45	\$67.10	\$64.20

GSK703151



## NeisVac-C

Each	5+	10+
\$83.95	\$82.45	\$75.85

BXTU67001



## Prevenar 13

Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed

Each	5+	10+	20+
\$140.35	\$135.00	\$133.10	\$132.00

XXP046




## Trumenba®

Meningococcal Group B Vaccine

Each	5+	10+
\$130.00	\$124.75	\$119.50

PHA33272



**Need to know a vaccine expiry date?**  
Log onto your account online  
[www.teammed.com.au/login](http://www.teammed.com.au/login)

**With Team Medical your vaccines arrive in peak condition. We maintain the highest standards and follow strict processes. For your peace of mind and for the integrity of our business.**



We successfully delivered over **1.6 million doses** of vaccines in 2023

